A rapid and durable response to larotrectinib in a patient with ntrk fusion-positive secretory carcinoma originating from the external auditory canal

HIGHLIGHTS

• who: Yuichi Ando from the Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital, Tsurumaiu2011cho, Showau2011ku, Nagoya, u20118550, Japan have published the research work: A rapid and durable response to larotrectinib in a patient with NTRK fusion-positive secretory carcinoma originating from the external auditory canal, in the Journal: (JOURNAL)
• what: The authors report the case of a patient with NTRK fusionpositive secretory carcinoma originating from the external auditory canal, who achieved a rapid and durable response to larotrectinib, an oral selective TRK inhibitor. This study was approved by the Institutional Ethics Committee (Approval No . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.